CryoPort (NASDAQ:CYRX) Hits New 12-Month High – Should You Buy?

Shares of CryoPort, Inc. (NASDAQ:CYRX) reached a new 52-week high on Thursday . The company traded as high as $14.68 and last traded at $14.6340, with a volume of 36519 shares. The stock had previously closed at $14.02.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CYRX. Weiss Ratings raised shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. BTIG Research boosted their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. KeyCorp boosted their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Craig Hallum started coverage on shares of CryoPort in a research note on Monday, March 30th. They set a “buy” rating and a $15.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.69.

CryoPort Stock Up 2.9%

The business has a fifty day moving average of $10.97 and a 200 day moving average of $9.85. The firm has a market cap of $790.78 million, a P/E ratio of 11.62 and a beta of 1.75.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The firm had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. On average, sell-side analysts expect that CryoPort, Inc. will post -0.74 EPS for the current fiscal year.

Insider Buying and Selling at CryoPort

In other CryoPort news, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the sale, the chief executive officer directly owned 1,054,501 shares in the company, valued at $8,436,008. This represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark W. Sawicki sold 3,235 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the sale, the insider owned 103,697 shares of the company’s stock, valued at $829,576. This trade represents a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 59,939 shares of company stock valued at $471,183. Corporate insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On CryoPort

Large investors have recently modified their holdings of the business. UBS Group AG increased its holdings in shares of CryoPort by 6.8% in the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock worth $13,650,000 after acquiring an additional 90,363 shares in the last quarter. Mak Capital One LLC bought a new stake in shares of CryoPort in the third quarter worth about $7,756,000. First Eagle Investment Management LLC bought a new stake in shares of CryoPort during the fourth quarter worth $2,996,000. Legato Capital Management LLC bought a new stake in shares of CryoPort during the fourth quarter worth $443,000. Finally, Segall Bryant & Hamill LLC bought a new stake in shares of CryoPort during the third quarter worth $652,000. 92.90% of the stock is currently owned by institutional investors.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.